Search results
Results From The WOW.Com Content Network
AstraZeneca's primary listing is on the London Stock Exchange and is a constituent of the FTSE 100 Index; it also has a secondary listing on the Nasdaq Stockholm. It is also listed on the American Nasdaq and is a Nasdaq-100 company. AstraZeneca has one of the highest market capitalisations of pharmaceutical companies worldwide. [14]
The Financial Times reported this was comprised of £70m in grants to develop an existing AstraZeneca facility at the same location, plus £20m in research and development support from the UK ...
AstraZeneca ditches £450m investment in UK plant January 31, 2025 at 10:39 AM AstraZeneca has scrapped plans to invest £450m in expanding a vaccine manufacturing plant in Liverpool, blaming a ...
Around two million doses of AstraZeneca and Oxford University's COVID-19 vaccine are set to be supplied every week by the middle of January in the UK, according to The Times newspaper. Britain ...
Li Ka Shing Centre of the Cancer Research UK Cambridge Institute. The Cancer Research UK Cambridge Institute is one of four core funded Cancer Research UK Institutes [11] and a department of the University of Cambridge. In 2018, the department received an annual budget of £45 million, £27.8 million of which came from Cancer Research UK.
A packet of AstraZeneca COVID-19 vaccine vials. A dispute broke out in January 2021 between the European Commission and the pharmaceutical company AstraZeneca AB about the provision of COVID-19 vaccines during the COVID-19 pandemic, [1] and, in February, spilled out into a dispute over Article 16 of the Northern Ireland Protocol.
British finance minister Rachel Reeves wants to reduce state provisions to the company's vaccine centre, which will cut the pledge made by the previous administration from about 90 million pounds ...
[106] [107] Trials were resumed on 13 September after AstraZeneca and Oxford, along with UK regulators, concluded it was safe to do so. [108] AstraZeneca was later criticised for refusing to provide details about potentially serious neurological side effects in two trial participants who had received the experimental vaccine in the UK. [109]